Described herein are composition of ascarosides, methods of using them, and the like for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for modifying a microbiome of a patient (e.g., for treatment of gut microbiome dysfunction).

The present disclosure provides a therapy for diabetes that targets abnormal stem cells in combination with stem cell migration. In one embodiment, the present disclosure provides a therapy for diabetes and/or diabetes-related diseases and disorders and/or symptoms that targets abnormal stem cells in combination with stem cell migration. In one embodiment, the present disclosure provides diagnosis of diabetes and/or diabetes-related diseases and disorders and/or symptoms, or the risk thereof, using abnormal stem cell migration and/or residence as an indicator.

A powdered composition is disclosed, the powdered composition comprising a complex between one or more cannabinoids having at least one phenolic moiety and a basic ion exchange resin. Also, an orally dispensable delivery vehicle, a method of manufacturing the powdered composition, a method of manufacturing the orally dispensable delivery vehicle, composition for use as a medicament, composition for use in a treatment, method of treatment, and use of a basic ion exchange resin as a stabilizing agent are disclosed.

Compositions comprising microbiome regulators are provided, as well as methods of using the same for the modulation of the human microbiota and to treat or prevent related diseases, disorders, or conditions.

Provided is a composition functioning to improve personalized gut microbiota diversity function. The composition includes ingredients for strengthening spleen and invigorating Qi, ingredients for clearing damp and promoting the circulation of blood, and intestinal bacteria substrates. The ingredients for strengthening spleen and invigorating Qi include one or more of Panax ginseng, an extract of Panax ginseng, Panax quiquefolium, and an extract of Panax quiquefolium; the ingredients for clearing damp and promoting the circulation of blood include an ingredient for clearing damp and an ingredient for promoting the circulation of blood, where the ingredient for clearing damp includes one of or a mixture of more of Wolfiporia cocos and an extract of Wolfiporia cocos, and the ingredient for promoting the circulation of blood includes one of or a mixture of more of nattokinase, natto, and an extract of natto; the intestinal bacteria substrates include water-soluble dietary fiber, water-insoluble dietary fiber, or any combination thereof.

The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and/or treatment of bacterial infections and antibacterial-induced dysfunctions. The invention is based on the identification of compounds that prevent antibacterial effects of antibiotics on microbiome-bacterial species, while retaining antibacterial effects of antibiotics on pathogenic bacteria. The invention also pertains to pharmaceutical compositions comprising antibiotics and antibiotic antidotes for the protection of commensal microbiome-bacteria. Thus, this invention relates to compounds and pharmaceutical combinations useful to prevent antibiotic-induced adverse effects on the gut microbiome. Furthermore provided are methods for preventing an adverse effect on a gut microbiome using the compounds and/or pharmaceutical compositions of this invention.

The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and/or treatment of bacterial infections and antibacterial-induced dysfunctions. The invention is based on the identification of compounds that prevent antibacterial effects of antibiotics on microbiome-bacterial species, while retaining antibacterial effects of antibiotics on pathogenic bacteria. The invention also pertains to pharmaceutical compositions comprising antibiotics and antibiotic antidotes for the protection of commensal microbiome-bacteria. Thus, this invention relates to compounds and pharmaceutical combinations useful to prevent antibiotic-induced adverse effects on the gut microbiome. Furthermore provided are methods for preventing an adverse effect on a gut microbiome using the compounds and/or pharmaceutical compositions of this invention.

The present disclosure provides technologies for modulating microbiome of mammalian subjects (e.g., human subjects). The present disclosure, among others, provides therapeutic compositions and methods of using the same, wherein the therapeutic compositions comprising an engineered population of therapeutic bacteria that (i) are non-pathogenic and commensal in a subject to be administered; and (ii) are resistant to one or more target bacteriophages. In some embodiments, such therapeutic compositions can be useful for treatment of subjects suffering from or susceptible to a microbiome-dysfunction-associated disease, disorder, or condition (e.g., inflammatory bowel disease).

The present disclosure provides technologies for modulating microbiome of mammalian subjects (e.g., human subjects). The present disclosure, among others, provides therapeutic compositions and methods of using the same, wherein the therapeutic compositions comprising an engineered population of therapeutic bacteria that (i) are non-pathogenic and commensal in a subject to be administered; and (ii) are resistant to one or more target bacteriophages. In some embodiments, such therapeutic compositions can be useful for treatment of subjects suffering from or susceptible to a microbiome-dysfunction-associated disease, disorder, or condition (e.g., inflammatory bowel disease).

The invention concerns a trans-splicing RNA (tsRNA) molecule comprising one or multiple unstructured binding domains; a cell or vector comprising said tsRNA; and a method for killing cells or treating a disease using said tsRNA.